91 related articles for article (PubMed ID: 2606582)
1. Ki67 and 4F2 antigen expression as well as DNA synthesis predict survival at relapse/tumour progression in low-grade B-cell lymphoma.
Holte H; de Lange Davies C; Beiske K; Stokke T; Marton PF; Smeland EB; Høie J; Kvaløy S
Int J Cancer; 1989 Dec; 44(6):975-80. PubMed ID: 2606582
[TBL] [Abstract][Full Text] [Related]
2. The activation-associated antigen 4F2 predicts patient survival in low-grade B-cell lymphomas.
Holte H; Davies CD; Kvaløy S; Smeland EB; Foss-Abrahamsen A; Kaalhus O; Marton PF; Godal T
Int J Cancer; 1987 May; 39(5):590-4. PubMed ID: 3106247
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma.
Salter DM; Krajewski AS; Sheehan T; Turner G; Cuthbert RJ; Mclean A
J Pathol; 1989 Nov; 159(3):211-20. PubMed ID: 2593045
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of lymphoma-specific S-phase fraction compared with that of other cell proliferation markers.
Holte H; Suo Z; Smeland EB; Kvaløy S; Langholm R; Stokke T
Acta Oncol; 1999; 38(4):495-503. PubMed ID: 10418718
[TBL] [Abstract][Full Text] [Related]
5. Expression of the activation antigen, 4F2, by non-Hodgkin's lymphomas of B-cell phenotype.
Lewandrowski KB; Medeiros LJ; Harris NL
Cancer; 1990 Sep; 66(6):1158-64. PubMed ID: 1698116
[TBL] [Abstract][Full Text] [Related]
6. MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas.
Pich A; Ponti R; Valente G; Chiusa L; Geuna M; Novero D; Palestro G
J Clin Pathol; 1994 Jan; 47(1):18-22. PubMed ID: 7907607
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas.
Korkolopoulou P; Angelopoulou M; Siakantari M; Mitropoulos F; Vassilakopoulos T; Zorzos H; Rassidakis G; Androulaki A; Patsouris E; Kittas C; Davaris P; Pangalis GA
Histopathology; 2001 Jan; 38(1):45-53. PubMed ID: 11135046
[TBL] [Abstract][Full Text] [Related]
8. Biologic progression in non-Hodgkin's lymphoma. A flow cytometric study.
Joensuu H; Klemi PJ; Jalkanen S
Cancer; 1990 Jun; 65(11):2564-71. PubMed ID: 2337874
[TBL] [Abstract][Full Text] [Related]
9. Transferrin receptor and B-lymphoblast antigen--their relationship to DNA synthesis, histology and survival in B-cell lymphomas.
Kvaløy S; Langholm R; Kaalhus O; Michaelsen T; Funderud S; Foss Abrahamsen A; Godal T
Int J Cancer; 1984 Feb; 33(2):173-7. PubMed ID: 6319299
[TBL] [Abstract][Full Text] [Related]
10. Proliferation markers in non-Hodgkin's lymphoma. A comparative study between cytophotometric quantitation of Ki-67 and flow cytometric proliferation index on fine needle aspirates.
Katz RL; Wojcik EM; el-Naggar AK; Ordonez NG; Johnston DA
Anal Quant Cytol Histol; 1993 Jun; 15(3):179-86. PubMed ID: 8347257
[TBL] [Abstract][Full Text] [Related]
11. PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis.
Novelli S; Briones J; Flotats A; Sierra J
Adv Clin Exp Med; 2015; 24(2):325-30. PubMed ID: 25931367
[TBL] [Abstract][Full Text] [Related]
12. DNA image cytometry and the expression of proliferative markers (proliferating cell nuclear antigen and Ki67) in non-Hodgkin's lymphomas.
Czader M; Porwit A; Tani E; Ost A; Mazur J; Auer G
Mod Pathol; 1995 Jan; 8(1):51-8. PubMed ID: 7731942
[TBL] [Abstract][Full Text] [Related]
13. Expression of three cell proliferation-associated antigens, DNA polymerase alpha, Ki-67 antigen and transferrin receptor in nodal and cutaneous T-cell lymphomas.
Mitani S; Tango T; Sonobe Y; Baba N; Nagatani T; Nomoto S; Mori S
Int J Hematol; 1991 Oct; 54(5):385-93. PubMed ID: 1756249
[TBL] [Abstract][Full Text] [Related]
14. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD95 antigen and Bcl-2 protein in non-Hodgkin's lymphomas and Hodgkin's disease.
Nguyen PL; Harris NL; Ritz J; Robertson MJ
Am J Pathol; 1996 Mar; 148(3):847-53. PubMed ID: 8774139
[TBL] [Abstract][Full Text] [Related]
16. Flow cytometry vs. Ki67 labelling index in breast cancer: a prospective evaluation of 181 cases.
Martínez-Arribas F; Núñez MJ; Piqueras V; Lucas AR; Sánchez J; Tejerina A; Schneider J
Anticancer Res; 2002; 22(1A):295-8. PubMed ID: 12017306
[TBL] [Abstract][Full Text] [Related]
17. Biological heterogeneity of diffuse mixed small and large cell non-Hodgkin's lymphomas assessed by DNA flow cytometry and Ki67.
Palestro G; Pich A; Chiusa L; Geuna M; Ponti R; Kerim S; Novero D; Valente G
Leuk Lymphoma; 1995 Nov; 19(5-6):467-72. PubMed ID: 8590848
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Ki67 evaluated by flow cytometry in dogs with high-grade B-cell lymphoma.
Poggi A; Miniscalco B; Morello E; Gattino F; Delaude A; Ferrero Poschetto L; Aresu L; Gelain ME; Martini V; Comazzi S; Riondato F
Vet Comp Oncol; 2017 Jun; 15(2):431-440. PubMed ID: 26792094
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma.
Hall PA; Richards MA; Gregory WM; d'Ardenne AJ; Lister TA; Stansfeld AG
J Pathol; 1988 Mar; 154(3):223-35. PubMed ID: 2450981
[TBL] [Abstract][Full Text] [Related]
20. MIB1 (Ki-67) expression in non-Hodgkin's lymphomas.
Kalogeraki A; Tzardi M; Panagiotides I; Koutsoubi K; Bolioti S; Rontogianni D; Stefanaki K; Zois E; Karidi E; Darivianaki K; Delides G; Kanavaros P
Anticancer Res; 1997; 17(1A):487-91. PubMed ID: 9066700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
